VANCOUVER, British Columbia & DALLAS / Dec 01, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Alpha Cognition will participate in an upcoming virtual fireside chat hosted by Boris Peaker of Titan Partners. The discussion will focus on... Read More

Key Highlights ZUNVEYL Launch Momentum: Completed the second quarter of commercialization, generating approximately $2.8 million in total revenue for the quarter. Significant Growth: 102% quarterly increase in pharmacy orders, with record prescription volumes achieved each month during the quarter. Expanding Prescriber Base: Q3 prescribers surpassed 500, representing 55% growth over the prior quarter. Disciplined Expense... Read More

Management to host conference call on Thursday, November 13, 2025 at 4:30pm ET VANCOUVER, British Columbia & DALLAS / Oct 30, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025, at 4:30... Read More

VANCOUVER, British Columbia & DALLAS / Oct 14, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at two upcoming scientific meetings: the American Society of... Read More

VANCOUVER, British Columbia & DALLAS / Oct 06, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL ® (Benzgalantamine) at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, October 23–25, 2025. On October 24,... Read More

Offering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareholders Company’s total cash position expected to be approximately $70 million following closing VANCOUVER, British Columbia & DALLAS / Sep 30, 2025 / Business Wire / Alpha Cognition Inc . (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company dedicated to developing innovative... Read More

VANCOUVER, British Columbia & DALLAS / Sep 30, 2025 / Business Wire / Alpha Cognition Inc. ( Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that it is proposing to offer and sell its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares, in an... Read More

VANCOUVER, British Columbia & DALLAS / Aug 28, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael McFadden will present at two prominent healthcare investor conferences this September. Cantor Global Healthcare Conference 2025 Date/Time:... Read More

Key Highlights ZUNVEYL Launch Momentum: Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Advancing ALPHA-1062: Completed pre-clinical Bomb Blast study in collaboration with the U.S. Department of Defense and the Seattle Institute of Biomedical and Clinical Research. Strong Balance Sheet: Cash and cash equivalents of $39.4 million as of June 30,... Read More

Conference Call Scheduled for August 14, 2025 4:30pm ET VANCOUVER, British Columbia & DALLAS / Aug 04, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a... Read More

VANCOUVER, British Columbia & DALLAS / Jul 29, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China... Read More

VANCOUVER, British Columbia & DALLAS / Jul 08, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada.... Read More

VANCOUVER, British Columbia & DALLAS / Jul 01, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data provides additional... Read More

Launched ZUNVEYL (benzgalantamine) to US market on March 17, 2025 Secured business development licensing revenues of $2.6M for partnership with CMS Pharma Cash and cash equivalents of $45.5 million as of March 31, 2025, compared to $48.6 million as of December 31, 2024. At current cash utilization rates, the Company expects a cash runway of approximately two years. VANCOUVER, British Columbia / May 15, 2025 / Business Wire /... Read More

Conference Call Scheduled for May 15, 2025 4:30pm ET VANCOUVER, British Columbia & DALLAS / May 01, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a... Read More

Grapevine, Texas--(Newsfile Corp. - April 30, 2025) - Alpha Cognition, Inc. (NASDAQ: ACOG), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City. Michael McFadden, CEO, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET). To register for one-on-one meetings with management at The Plaza Hotel in New... Read More

VANCOUVER, British Columbia & DALLAS / Apr 28, 2025 / Business Wire / Alpha Cognition Inc. (NASDAQ: ACOG) (the “Company” or “Alpha Cognition”) today announced three upcoming presentations at the 2025 Alzheimer’s Association International Conference (the “AAIC”), taking place July 27–31, 2025 in Toronto, Canada. The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company’s lead product... Read More

VANCOUVER & DALLAS / Apr 10, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and... Read More

Dallas, Texas--(Newsfile Corp. - April 1, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition had a strong 2024 after raising $52.8M and uplisting to NASDAQ, significantly enhancing its capital base and market visibility. It completed commercial manufacturing for its lead product ZUNVEYL (benzgalantamine), secured a new U.S.... Read More

Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial manufacturing to support the ZUNVEYL launch. Successfully completed the first phase of a pre-clinical bomb-blast study funded by a Department of Defense grant, demonstrating benzgalantamine’s efficacy and safety in treating head trauma from simulated bomb blasts. Cash... Read More

Conference Call Scheduled for March 31, 2025 4:30pm ET VANCOUVER, British Columbia & DALLAS / Mar 19, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the... Read More

ZUNVEYL is the first oral FDA-approved treatment for Alzheimer’s disease in the past decade 32 person sales team hired to cover the $2 billion Long-Term-Care market All launch activities delivered on-time and on-budget, positioning ZUNVEYL for success VANCOUVER, British Columbia & DALLAS / Mar 18, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for... Read More

VANCOUVER / Feb 12, 2025 / Business Wire / Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent titled “Coated Tablets for pH-Dependent Release of Benzgalantamine.” This newly issued patent... Read More

VANCOUVER, British Columbia & DALLAS / Jan 14, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa , Vice President of Commercial; Jack Kelly , Head of Market Access; Rommel Fernandez , Vice President of Corporate... Read More

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )-- Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People’s... Read More

VANCOUVER, British Columbia & DALLAS / Dec 16, 2024 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced that the underwriters of its underwritten U.S. public offering (the “Offering”) have partially exercised their over-allotment option to purchase an... Read More

VANCOUVER, British Columbia & DALLAS / Dec 12, 2024 / Business Wire / Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company’s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange. The shares will be delisted from the Canadian Securities Exchange at the close of trading on December 17,... Read More

VANCOUVER, British Columbia & DALLAS / Dec 11, 2024 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced interim preclinical data that supports the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The interim... Read More

VANCOUVER, British Columbia / Nov 15, 2024 / Business Wire / Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended September 30, 2024, and provided a corporate update. “The FDA approval of ZUNVEYL represents an... Read More

VANCOUVER, British Columbia / Nov 12, 2024 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the pricing of its upsized public offering of 8,695,653 common shares at a public offering price of $5.75 per share, for gross proceeds of... Read More

VANCOUVER, British Columbia / Oct 31, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), is pleased to announce that it has filed a registration statement on Form S-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission relating to a firm commitment public offering of common shares and pre-funded warrants (collectively, the “Securities”)... Read More

VANCOUVER, British Columbia / Oct 21, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Henry Du has joined Alpha Cognition as the VP of... Read More

VANCOUVER, British Columbia / Oct 15, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 18/434,155, entitled “Coated... Read More

VANCOUVER, British Columbia / Oct 03, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Don Kalkofen has resigned as the Chief Financial Officer of the Company to pursue other opportunities. “On behalf of Alpha Cognition, I want to... Read More

VANCOUVER, British Columbia / Sep 24, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the closing of a $4.545 million bridge financing through the offer of convertible notes and warrants. The financing was led by existing investors and... Read More

VANCOUVER, British Columbia / Aug 19, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 18/463,157, entitled “Solid Forms... Read More

VANCOUVER, British Columbia & DALLAS / Aug 13, 2024 / Business Wire / Alpha Cognition (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, announced today its decision to temporarily delay its planned capital raise and uplisting to the NASDAQ Capital Market due to current challenging market conditions. The... Read More

VANCOUVER, British Columbia / Aug 12, 2024 / Business Wire / Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended June 30, 2024, and provided a corporate update. “The FDA approval of ZUNVEYL represents an important... Read More

The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Eliminate Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading Alzheimer’s Disease (AD) Medications, Combined with a Long-Term Efficacy Profile ZUNVEYL’s Innovative Approach Targets AD Symptoms Directly, Designed to Provide Patients with Significant Benefits to Cognitive and Global... Read More

VANCOUVER, British Columbia / May 14, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter of 2024 and provided a corporate update. "Alpha Cognition... Read More

VANCOUVER, British Columbia / Apr 03, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended 2023 and provided a corporate update.... Read More

VANCOUVER, British Columbia / Mar 20, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it will present at the Emerging Growth Conference on April 3, 2024. The company invites individual and institutional investors as well as advisors and analysts, to attend its real-time,... Read More

VANCOUVER, British Columbia / Feb 22, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the... Read More

VANCOUVER, British Columbia / Feb 12, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercialization strategy, and a pipeline update. The Company completed a transformational year as... Read More

VANCOUVER, British Columbia / Jan 19, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company. Pursuant to the final closing, the Company issued 16,965,762 units of the Company at a price of US$0.22 per unit for gross proceeds of US$3,732,467.... Read More

VANCOUVER, British Columbia / Dec 22, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a fourth closing pursuant to its previously announced private placement of units of the Company. Pursuant to the fourth closing, the Company issued 9,141,534 units of the Company at a price of US$0.22 per unit for gross proceeds of US$2,011,138.... Read More

VANCOUVER, British Columbia / Dec 07, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) has completed its filing review and has accepted the company’s New Drug Application (NDA) for... Read More

VANCOUVER, British Columbia / Dec 04, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has amended the terms of its previously announced private placement offering of up to US$6.5 million of units at a price of US$0.22 per unit. Each unit will now consist of one common share and one share purchase warrant. Each warrant will entitle the holder to... Read More

VANCOUVER, British Columbia / Nov 28, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the third quarter and nine months ended September 30, 2023, and provided a... Read More

VANCOUVER, British Columbia / Nov 08, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a third closing pursuant to its previously announced private placement of units of the Company. Pursuant to the third closing, the Company issued 4,590,903 units of the Company at a price of US$0.22 per unit for gross proceeds of US$1,009,999.... Read More

VANCOUVER, British Columbia / Sep 27, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALPHA-1062, a proprietary, patented, delayed... Read More

VANCOUVER, British Columbia / Aug 31, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”) announces the closing of its previously announced private placement of units of the Company for gross proceeds of US$1,345,093 before deducting the placement agent’s fees and other offering expenses payable by the Company. Pursuant to the closing, the Company issued a total of... Read More

VANCOUVER, British Columbia / Aug 22, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended June 30, 2023, and provided a... Read More

VANCOUVER, British Columbia / Aug 14, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 17/575,025, titled “Solid Forms... Read More

VANCOUVER, BC / ACCESSWIRE / April 5, 2023 / Alpha Cognition Inc. (TSX-V:ACOG) (OTCQB:ACOGF), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 10:30AM (Local Time -PST). Michael McFadden, CEO of Alpha Cognition, will be hosting the presentation and... Read More

VANCOUVER, British Columbia / Mar 08, 2023 / Business Wire / Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a... Read More

VANCOUVER, British Columbia / Mar 06, 2023 / Business Wire / Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, announces that the Company expects to complete the second tranche of its ongoing private placement offering prior to March 17, 2023. Please see the Company’s February 16,... Read More

VANCOUVER, British Columbia / Feb 16, 2023 / Business Wire / Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, is pleased to announce that it has closed the first tranche of its previously announced private placement (the “ Offering ”). Pursuant to the Offering, the Company issued... Read More

VANCOUVER, British Columbia / Feb 08, 2023 / Business Wire / Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce a private placement financing of units for gross proceeds of up to C$6.8 million... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announced today that it has cancelled an aggregate of 4,655,000 incentive stock options with exercise prices ranging from $0.64 CAD to $1.05 CAD. The board of directors... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced that the company's Chief Medical Officer (CMO), Cedric O’Gorman, MD has resigned to pursue other opportunities. The company has undertaken a search for a... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022. "The Company released positive topline data from the ALPHA-1062... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces that the European Patent Office has confirmed the patentability of EP3009143 in amended form following an opposition proceeding involving two opponents. The... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the discovery of two GEM combinations, ALPHA-0702 and ALPHA-0802, and positive preclinical data from each candidate therapy. ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announces the grant of stock options pursuant to its stock option plan to certain directors of the Company to purchase up to an aggregate of 400,000 common shares of the... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2022. "The Company is on track and plans to release data from the ALPHA-1062 pivotal trial during the... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021. "This past quarter and the year leading up to it has been a transformational... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces the appointment of Don Kalkofen as Chief Financial Officer (CFO) to replace Jeremy Wright. Mr. Wright will continue to assist the Company in a consulting... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce positive preclinical data from their ALPHA-0602 ALS gene therapy program. These data underscore the robust preclinical evidence supporting... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce histology data from their intranasal ALPHA-1062 Traumatic Brain Injury (TBI) program. ALPHA-1062 treatment was neuroprotective, preserving... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is scheduled to participate in the following investor conferences in January 2022: LifeSci Advisors Partners Corporate Access Event, January 5-7 The Company will be... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the resignation of Dr. Fred Sancilio from his role as Director and President of the Company. Dr. Sancilio will continue to work with Alpha Cognition as a... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program. ALPHA-1062 administration significantly, acutely reduced the... Read More

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the appointment of Cedric O’Gorman, M.D., as the Company’s Chief Medical Officer. Dr. O’Gorman will lead medical, clinical and regulatory functions in support... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB:ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it has reported its Third Quarter financial results of fiscal 2021. Select Financial Information for Q3-2021: (for the period ended September 30,... Read More